QRL Bioscience, a cutting-edge biotechnology startup dedicated to developing personalised, cell-based therapies for chronic degenerative diseases, has raised Rs 3 crore in its latest funding round from GVFL, one of India’s pioneering venture capital firms.
Founded initially with a vision to transform the treatment of (DFU) and Osteoarthritis, Ahmedabad-based QRL Bioscience is spearheading a new era of regenerative medicine in India.
The fresh capital infusion from GVFL will be utilised to accelerate the clinical trial phase of its DFU therapy and support the preclinical development of its osteoarthritis treatment.
QRL previously raised a seed fund from Tie India Angel investors. QRL Bioscience plans to deploy the capital strategically over the next 22 months. The majority of the funds will support the ongoing DFU clinical trial, while the remainder will be allocated to advancing the osteoarthritis treatment product, including formulation development and regulatory preparations.
Dr Senthil Natesan, Co-founder of QRL Bioscience, said, “We are building an Indian company with a global vision by creating truly novel solutions to improve human health worldwide. Our pioneering personalised medicine using living cell-based therapies will address long-standing health challenges. This funding will bring our DFU product closer to market readiness and advance our osteoarthritis therapy to its next major milestone. We are grateful for the confidence GVFL has placed in us and look forward to welcoming additional strategic partners in this round.”
QRL Bioscience has made significant progress since its last funding round. These include initiating clinical groundwork for DFU therapy and achieving key research milestones in osteoarthritis treatment. The company has also laid a strong foundation for market readiness by engaging doctors, identifying distribution channels, and strengthening its supply chain capabilities.
The company is also exploring co-development and co-marketing partnerships in the orthopaedic space to accelerate its go-to-market strategy.
